Down syndrome and Alzheimer's disease: Common pathways, common goals
Down syndrome and Alzheimer's disease: Common pathways, common goals
复制标题
DOI：
10.1016/j.jalz.2014.10.007
复制
发表时间：
2015-06-01
影响因子：
14
通讯作者：
Wisniewski, Thomas
中科院分区：
文献类型：
--
作者：
Hartley, Dean;Blumenthal, Thomas;Wisniewski, Thomas
在美国，估计有25万到40万人患有唐氏综合症(DS)，几乎所有人都会在30多岁时开始患上阿尔茨海默病(AD)的病理。目前的寿命是55岁到60岁，大约70%会患上痴呆症，如果他们的预期寿命继续增加，患AD的人数也会随之增加。DS和阿尔茨海默氏症之间的致病和机制联系促使阿尔茨海默氏症协会与Linda Crnic研究所唐氏综合症研究所和全球唐氏综合症基金会合作，在AD和DS专家研讨会上讨论该领域的异同、挑战和未来方向。讲习班阐明了一系列研究优先事项：(1)目标确定和药物开发，(2)临床和病理分期，(3)认知评估和临床试验，以及(4)伙伴关系和协作，最终目标是提供有效的疾病修正治疗。(C)2015年阿尔茨海默氏症协会。爱思唯尔公司出版，版权所有。
In the United States, estimates indicate there are between 250,000 and 400,000 individuals with Down syndrome (DS), and nearly all will develop Alzheimer's disease (AD) pathology starting in their 30s. With the current lifespan being 55 to 60 years, approximately 70% will develop dementia, and if their life expectancy continues to increase, the number of individuals developing AD will concomitantly increase. Pathogenic and mechanistic links between DS and Alzheimer's prompted the Alzheimer's Association to partner with the Linda Crnic Institute for Down Syndrome and the Global Down Syndrome Foundation at a workshop of AD and DS experts to discuss similarities and differences, challenges, and future directions for this field. The workshop articulated a set of research priorities: (1) target identification and drug development, (2) clinical and pathological staging, (3) cognitive assessment and clinical trials, and (4) partnerships and collaborations with the ultimate goal to deliver effective disease-modifying treatments. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.